Technology areas: Biotechnology & Pharmaceuticals • Transportation, E-Commerce & Mechanical Systems
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Atai Therapeutics, Inc. currently faces 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. The prosecution is decentralized, involving 4 distinct examiners. These examiners are situated within 3 distinct art units, showing a slight concentration of administrative oversight compared to the number of examiners. HEASLEY, MEGHAN CHRISTINE is the busiest examiner with 1 pending action, which is the same count held by the other 3 distinct examiners.
For a practitioner, this distribution means that while the 4 pending office actions are spread across 4 individuals, some of those individuals likely work within the same art unit. Specifically, the 4 examiners are housed in only 3 distinct art units. This structure requires the practitioner to navigate the preferences of 4 different people while potentially dealing with the shared internal policies of the 3 art units. The focus on Biotechnology & Pharmaceuticals suggests these 4 actions involve complex biological or chemical subject matter. Managing 4 pending office actions across 4 distinct examiners requires a high level of coordination to maintain consistency in the company's legal and technical arguments.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (25%) |
| Double-patenting + other | 2 (50%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HEASLEY, MEGHAN CHRISTINE | 1 | 74.5% | +36.3% |
| MOORE, SUSANNA | 1 | 68.0% | +31.6% |
| BURGESS, JOSEPH D | 1 | 39.7% | +35.7% |
| PATEL, SAGAR S | 1 | 75.7% | +34.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18504056 | SYSTEMS, DEVICES, AND METHODS FOR EVENT-BASED KNOWLEDGE REASONING SYSTEMS USING ACTIVE AND PASSIVE SENSORS FOR PATIENT MONITORING AND FEEDBACK | BURGESS, JOSEPH D | 30d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18504056 | SYSTEMS, DEVICES, AND METHODS FOR EVENT-BASED KNOWLEDGE REASONING SYSTEMS USING ACTIVE AND PASSIVE SENSORS FOR PATIENT MONITORING AND FEEDBACK | BURGESS, JOSEPH D | 30d overdue |
| 18462120 | HETEROATOM SUBSTITUTED CYCLIC AND ALKYL AMINES AS ACTIVATORS OF SEROTONIN RECEPTORS | PATEL, SAGAR S | 14d |
| 18541172 | PRODRUGS OF DIMETHYLTRYPTAMINE AND DERIVATIVES THEREOF | HEASLEY, MEGHAN CHRISTINE | — |
| 18646264 | IBOGAINE AND NORIBOGAINE ANALOGS AND METHODS OF USE | MOORE, SUSANNA | — |
| Art Unit | Apps |
|---|---|
| 1626 | 2 |
| 1624 | 1 |
| 3685 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18541172 | PRODRUGS OF DIMETHYLTRYPTAMINE AND DERIVATIVES THEREOF | HEASLEY, MEGHAN CHRISTINE | 1626 | §102DP | Non-Final OA | — | Pending | May 01, 2024 |
| 18646264 | IBOGAINE AND NORIBOGAINE ANALOGS AND METHODS OF USE | MOORE, SUSANNA | 1624 | §102DP | Non-Final OA | — | Pending | Apr 25, 2024 |
| 18504056 | SYSTEMS, DEVICES, AND METHODS FOR EVENT-BASED KNOWLEDGE REASONING SYSTEMS USING ACTIVE AND PASSIVE SENSORS FOR PATIENT MONITORING AND FEEDBACK | BURGESS, JOSEPH D | 3685 | §102§103 | Final Rejection | 30d overdue | Pending | Nov 07, 2023 |
| 18462120 | HETEROATOM SUBSTITUTED CYCLIC AND ALKYL AMINES AS ACTIVATORS OF SEROTONIN RECEPTORS | PATEL, SAGAR S | 1626 | §102 | Non-Final OA | 14d | Pending | Sep 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAtai Therapeutics, Inc. has 4 pending office actions as of October 2026, spread across 3 art units and 4 examiners.
Meghan Christine Heasley has the most, with 1 of Atai Therapeutics, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
